Deciphera Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Le PDG Deciphera Pharmaceuticals est Steve Hoerter, nommé en Mar2019, a un mandat de 5.25 ans. La rémunération annuelle totale est $ 6.01M, composée du salaire de 12.3% et des bonus 87.7%, y compris les actions et options de la société. détient directement 0.084% des actions de la société, d'une valeur de $ 1.86M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.3 ans et 9 ans.

Informations clés

Steve Hoerter

Directeur général

US$6.0m

Rémunération totale

Pourcentage du salaire du PDG	12.3%
Durée du mandat du directeur général	5.3yrs
Propriété du PDG	0.08%
Durée moyenne d'occupation des postes de direction	4.3yrs
Durée moyenne du mandat des membres du conseil d'administration	9yrs

Mises à jour récentes de la gestion

Recent updates

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Apr 30

Diving Into Deciphera Pharmaceuticals

Apr 26

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Mar 13

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 02

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Sep 25

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Jul 26

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Jun 22

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

May 08

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Apr 10

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Dec 29

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Aug 29

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Aug 03

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Jul 29

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Feb 11

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Nov 22

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Aug 26

Deciphera Pharmaceuticals posts data from cancer studies at ASCO21

Jun 04

Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth

May 10

Analyse de la rémunération des PDG

Comment la rémunération de Steve Hoerter a-t-elle évolué par rapport aux bénéfices de Deciphera Pharmaceuticals?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Mar 31 2024	n/a	n/a	-US$190m
Dec 31 2023	US$6m	US$738k	-US$195m
Sep 30 2023	n/a	n/a	-US$194m
Jun 30 2023	n/a	n/a	-US$187m
Mar 31 2023	n/a	n/a	-US$182m
Dec 31 2022	US$4m	US$703k	-US$179m
Sep 30 2022	n/a	n/a	-US$221m
Jun 30 2022	n/a	n/a	-US$258m
Mar 31 2022	n/a	n/a	-US$286m
Dec 31 2021	US$9m	US$676k	-US$300m
Sep 30 2021	n/a	n/a	-US$274m
Jun 30 2021	n/a	n/a	-US$258m
Mar 31 2021	n/a	n/a	-US$255m
Dec 31 2020	US$8m	US$650k	-US$266m
Sep 30 2020	n/a	n/a	-US$271m
Jun 30 2020	n/a	n/a	-US$263m
Mar 31 2020	n/a	n/a	-US$218m
Dec 31 2019	US$9m	US$435k	-US$192m
Sep 30 2019	n/a	n/a	-US$157m
Jun 30 2019	n/a	n/a	-US$126m
Mar 31 2019	n/a	n/a	-US$126m
Dec 31 2018	US$447k	n/a	-US$100m

Rémunération vs marché: La rémunération totale de Steve ($USD 6.01M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 5.37M ).

Rémunération et revenus: La rémunération de Steve a augmenté alors que l'entreprise n'est pas rentable.

PDG

Steve Hoerter (53 yo)

5.3yrs

Titularisation

US$6,010,712

Compensation

Mr. Steven L. Hoerter, also known as Steve, serves as Director at ORIC Pharmaceuticals, Inc. since August 2021. He has been President and Chief Executive Officer of Deciphera Pharmaceuticals, Inc. since Ma...

Équipe de direction

Nom	Position	Titularisation	Compensation	Propriété
Steven Hoerter	President	5.3yrs	US$6.01m	0.084% $ 1.9m
Thomas Kelly	Executive VP	9.3yrs	US$2.03m	0.049% $ 1.1m
Dashyant Dhanak	Executive VP & Chief Scientific Officer	less than a year	US$3.06m	0% $ 0
Daniel Martin	Senior VP & Chief Commercial Officer	5.8yrs	US$1.58m	0.036% $ 801.7k
Matthew Sherman	Executive VP & Chief Medical Officer	4.7yrs	US$2.13m	0.084% $ 1.8m
Kevin Brodbeck	Senior VP & Chief Technical Officer	less than a year	pas de données	pas de données
Jennifer Larson	Senior Vice President of Finance & Investor Relations	no data	pas de données	pas de données
Jeffrey Held	Senior VP & General Counsel	5.3yrs	pas de données	pas de données
Lisa Price	Senior VP & Chief Human Resources Officer	2.4yrs	pas de données	pas de données
Jama Pitman	Senior VP & Chief Development Officer	4.3yrs	pas de données	0.040% $ 876.3k
Margarida Duarte	Senior VP & Head of International	3.3yrs	pas de données	pas de données
Rodrigo Soto	Senior Vice President of Clinical Development	3.4yrs	pas de données	pas de données

4.3yrs

Durée moyenne de l'emploi

53yo

Âge moyen

Gestion expérimentée: L'équipe de direction de DCPH est considérée comme expérimentée (ancienneté moyenne 4.3 ans).

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Steven Hoerter	President	6.1yrs	US$6.01m	0.084% $ 1.9m
John Martin	Independent Director	9.3yrs	US$388.59k	0% $ 0
Edward Benz	Independent Director	7.7yrs	US$396.09k	0% $ 0
Patricia L. Allen	Independent Director	7.8yrs	US$398.55k	0% $ 0
Ron Squarer	Independent Chairman	4.5yrs	US$403.30k	0% $ 0
Jean-Yves Blay	Member of Scientific Advisory Board	9yrs	pas de données	pas de données
James Bristol	Independent Director	16.8yrs	US$414.77k	0% $ 0
John Condeelis	Member of Scientific Advisory Board	no data	pas de données	pas de données
Filip Janku	Member of Scientific Advisory Board	9yrs	pas de données	pas de données
F. Hodi	Member of Scientific Advisory Board	9yrs	pas de données	pas de données
Dennis Walsh	Independent Director	9.3yrs	US$386.05k	0.013% $ 281.5k
John de Groot	Member of Scientific Advisory Board	no data	pas de données	pas de données

9.0yrs

Durée moyenne de l'emploi

62yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de DCPH sont considérés comme expérimentés (ancienneté moyenne 9 ans).

Deciphera Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Informations clés

Mises à jour récentes de la gestion

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

President recently sold US$471k worth of stock

Senior VP & Chief Commercial Officer recently sold US$224k worth of stock

President recently sold US$259k worth of stock

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Independent Director recently bought US$152k worth of stock

Recent updates

Deciphera Pharmaceuticals, Inc. Files Form 15

Deciphera Pharmaceuticals, Inc.(NasdaqGS:DCPH) dropped from NASDAQ Composite Index

Deciphera Pharmaceuticals Announces Oral Presentation of Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (Tgct) At the 2024 Asco Annual Meeting and Online Publication in the Lancet

First quarter 2024 earnings released: US$0.52 loss per share (vs US$0.60 loss in 1Q 2023)

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up

Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion.

Price target increased by 7.1% to US$25.38

Deciphera Pharmaceuticals, Inc., Annual General Meeting, Jun 20, 2024

Diving Into Deciphera Pharmaceuticals

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Full year 2023 earnings: EPS exceeds analyst expectations

Consensus estimates of losses per share improve by 12%

Deciphera Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Deciphera Pharmaceuticals, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Deciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18

President recently sold US$471k worth of stock

Senior VP & Chief Commercial Officer recently sold US$224k worth of stock

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President recently sold US$259k worth of stock

Price target increased by 11% to US$24.44

Deciphera Pharmaceuticals, Inc. Announces Positive Top-Line Results from Motion Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. Announces Board Changes, Effective from September 5, 2023

Deciphera Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans

Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)

Deciphera Pharmaceuticals, Inc. to Present Data from INTRIGUE Phase 3 Study of QINLOCK (ripretinib) and Trial-In-Progress Poster for Insights Pivotal Phase 3 Study of QINlock (Rpretinib) at the 2023 American Society of Clinical Oncology Annual Meeting

Independent Director recently bought US$152k worth of stock

Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S

First quarter 2023 earnings: EPS and revenues miss analyst expectations

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

President notifies of intention to sell stock

Full year 2022 earnings: EPS exceeds analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 07, 2023

Deciphera Pharmaceuticals, Inc. Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Executive VP recently sold US$51k worth of stock

Now 20% undervalued

Price target increased to US$21.10

Deciphera Pharmaceuticals, Inc. Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2022

Price target increased to US$20.25

Deciphera Pharmaceuticals, Inc. Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Deciphera Pharmaceuticals, Inc. Presents Updated Phase 1/2 Data for Vimseltinib in TGCT at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera Pharmaceuticals, Inc. Presents Initial Phase 1 Single Agent Dose Escalation Data for First-in-Class ULK Inhibitor of Autophagy, DCC-3116, at the European Society for Medical Oncology (ESMO) Congress 2022

Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside

Deciphera Pharmaceuticals, Inc. Announces Publication of Intrigue Phase 3 Clinical Study Results in Journal of Clinical Oncology

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals Q2 2022 Earnings Preview

Deciphera Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 04, 2022

We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully

Deciphera Pharmaceuticals, Inc. Appoints Kelley Dealhoy as Senior Vice President and Chief Business Officer

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Deciphera Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 04, 2022

Insufficient new directors

Deciphera Pharmaceuticals, Inc Presents Preclinical Data from DCC-3116 Program At the AACR Annual Meeting

Insufficient new directors

Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now

Deciphera Pharmaceuticals, Inc. to Report Q4, 2021 Results on Feb 08, 2022

Deciphera Pharmaceuticals, Inc. Presents Results from the INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals, Inc. Receives European Commission Approval of QINLOCK® for Treatment of Fourth-Line Gastrointestinal Stromal Tumor

Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified

Price target decreased to US$59.27